Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EISAI INC. via EISAI INC.
2015 · second_quarter · 2A
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
Source: Senate LDA
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
National Defense Authorization Act for Fiscal Year 2016
Client: EISAI INC. · Firm: EISAI INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
National Defense Authorization Act for Fiscal Year 2016
Client: EISAI INC. · Firm: EISAI INC.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Regulatory and legislative health care issues, including the 340B program HR6 - 21st Century Cures Act
Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Regulatory and legislative health care issues, including the 340B program HR6 - 21st Century Cures Act
Improving Regulatory Transparency for New Medical Therapies Act
Client: EISAI INC. · Firm: EISAI INC.
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
Improving Regulatory Transparency for New Medical Therapies Act
Client: EISAI INC. · Firm: EISAI INC.
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
Improving Regulatory Transparency for New Medical Therapies Act
Client: EISAI INC. · Firm: EISAI INC.
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
Improving Regulatory Transparency for New Medical Therapies Act
Client: EISAI INC. · Firm: EISAI INC.
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
SGR Repeal and Medicare Provider Payment Modernization Act of 2015
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Client: EISAI INC. · Firm: EISAI INC.
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Client: EISAI INC. · Firm: EISAI INC.
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
Client: EISAI INC. · Firm: EISAI INC.
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Regulatory and legislative health care issues, including the 340B program HR6 - 21st Century Cures Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI INC. via EISAI INC.
2015 · second_quarter · Q2
IP issues related to the Trade Promotion Authority and Trans Pacific Partnership HR 9/S 1137 - The Innovation Act/PATENT Act HR 1314/S 995 - Trade Act of 2015/Bipartisan Congressional Trade Priorities and Accountability Act of 2015
Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Regulatory and legislative health care issues, including the 340B program HR6 - 21st Century Cures Act
DoD/TRICARE coverage of FDA-approved obesity drugs National Defense Authorization Bill for 2016 (HR 1735/S 1376) Department of Defense Appropriations Bill for 2016 (HR 2685/S 1558)
DEA scheduling of controlled substances H.R. 639/S 481 - Improving Regulatory Transparency for New Medical Therapies Act
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 2 - Medicare Access and CHIP Reauthorization Act of 2015 S. 810 - SGR Repeal and Medicare Provider Payment Modernization Act of 2015 H.R. 2404/S 1509 - Treat and Reduce Obesity Act of 2015
Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of obesity Rx products H Con Res 27 - Establishing the budget for the United States Government for FY 2016 and setting forth appropriate budgetary levels for FYs 2017 through 2025. S Con Res 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for Fiscal Year 2016 and setting for the appropriate budgetary levels for fiscal years 2017 through 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE